Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

Humans are less sensitive to the therapeutic effects of botulinum neurotoxin B (BoNT/B) than the animal models it is tested on due to differences between the human and the mouse receptors. Here, the authors engineer BoNT/B to improve its affinity to human receptors and enhance its therapeutic effica...

Full description

Bibliographic Details
Main Authors:	Liang Tao, Lisheng Peng, Ronnie P.-A. Berntsson, Sai Man Liu, SunHyun Park, Feifan Yu, Christopher Boone, Shilpa Palan, Matthew Beard, Pierre-Etienne Chabrier, Pål Stenmark, Johannes Krupp, Min Dong
Format:	Article
Language:	English
Published:	Nature Publishing Group 2017-07-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-017-00064-y

id	doaj-c4a98be4d71a49939f118b13ff4c9b03
record_format	Article
spelling	doaj-c4a98be4d71a49939f118b13ff4c9b032021-01-31T12:34:25ZengNature Publishing GroupNature Communications2041-17232017-07-018111010.1038/s41467-017-00064-yEngineered botulinum neurotoxin B with improved efficacy for targeting human receptorsLiang Tao0Lisheng Peng1Ronnie P.-A. Berntsson2Sai Man Liu3SunHyun Park4Feifan Yu5Christopher Boone6Shilpa Palan7Matthew Beard8Pierre-Etienne Chabrier9Pål Stenmark10Johannes Krupp11Min Dong12Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolDepartment of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolDepartment of Biochemistry and Biophysics, Stockholm UniversityIPSEN BioinnovationDepartment of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolDepartment of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolDepartment of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolIPSEN BioinnovationIPSEN BioinnovationIPSEN InnovationDepartment of Biochemistry and Biophysics, Stockholm UniversityIPSEN BioinnovationDepartment of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical SchoolHumans are less sensitive to the therapeutic effects of botulinum neurotoxin B (BoNT/B) than the animal models it is tested on due to differences between the human and the mouse receptors. Here, the authors engineer BoNT/B to improve its affinity to human receptors and enhance its therapeutic efficacy.https://doi.org/10.1038/s41467-017-00064-y
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Liang Tao Lisheng Peng Ronnie P.-A. Berntsson Sai Man Liu SunHyun Park Feifan Yu Christopher Boone Shilpa Palan Matthew Beard Pierre-Etienne Chabrier Pål Stenmark Johannes Krupp Min Dong
spellingShingle	Liang Tao Lisheng Peng Ronnie P.-A. Berntsson Sai Man Liu SunHyun Park Feifan Yu Christopher Boone Shilpa Palan Matthew Beard Pierre-Etienne Chabrier Pål Stenmark Johannes Krupp Min Dong Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors Nature Communications
author_facet	Liang Tao Lisheng Peng Ronnie P.-A. Berntsson Sai Man Liu SunHyun Park Feifan Yu Christopher Boone Shilpa Palan Matthew Beard Pierre-Etienne Chabrier Pål Stenmark Johannes Krupp Min Dong
author_sort	Liang Tao
title	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
title_short	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
title_full	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
title_fullStr	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
title_full_unstemmed	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
title_sort	engineered botulinum neurotoxin b with improved efficacy for targeting human receptors
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2017-07-01
description	Humans are less sensitive to the therapeutic effects of botulinum neurotoxin B (BoNT/B) than the animal models it is tested on due to differences between the human and the mouse receptors. Here, the authors engineer BoNT/B to improve its affinity to human receptors and enhance its therapeutic efficacy.
url	https://doi.org/10.1038/s41467-017-00064-y
work_keys_str_mv	AT liangtao engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT lishengpeng engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT ronniepaberntsson engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT saimanliu engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT sunhyunpark engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT feifanyu engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT christopherboone engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT shilpapalan engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT matthewbeard engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT pierreetiennechabrier engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT palstenmark engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT johanneskrupp engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors AT mindong engineeredbotulinumneurotoxinbwithimprovedefficacyfortargetinghumanreceptors
_version_	1724317231496560640

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

Similar Items